Pricing Log in Create free account
Saturday 31 October 2026 Export AMGN’s income statement to Excel — free account

Amgen Inc.

AMGN Healthcare Drug Manufacturers General

Amgen Inc.’s revenue for fiscal 2025 (year ended December 2025) was $36.8 billion, up 9.95% from fiscal 2024. In the quarter to June 2026, revenue grew 9.53%, EPS grew 65.4%, free cash flow grew 82.6% and total debt rose 1.96%, each against the same quarter a year earlier. Member of the S&P 500, Nasdaq 100 and Dow Jones; dividend growth for ten consecutive years, revenue growth for five.

466.16 5.43 +1.18%
Market cap
$249.1B
P/E
28.7×
Fwd P/E
29.6×
Dividend yield
2.67%
F-score
7/9
Altman Z
1.69
Beneish M
−2.27
Dividend safety
56/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Amgen Inc. 8-K filed Aug 5, 2025

Period ended Aug 5, 2025 · Filed · accepted 4:03 PM ET · Document on sec.gov · Filing index

2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits

Nothing in this filing raised a red flag, and we have no summary of it. The items it reports are listed above; the document itself is on sec.gov.

Read the filing on sec.gov The press release